FDA analysis of J&J COVID vaccine booster sets the stage for public hearing

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 13, 2021 at 11:02 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via A Food and Drug Administration analysis of Johnson & Johnson's application for authorization of its COVID vaccine booster tees up deliberations at a public meeting of agency advisers Friday. The document was posted Wednesday.

    The questions that will be put before the committee will include whether the data supports the safety and effectiveness of a booster dose of the company's COVID vaccine after at least two months have elapsed since initial immunization with the one-shot vaccine and whether the data shows that there is a stronger response at a six-month interval as well.

    article source